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Fibroblast Growth Factor Receptors (FGFR1–4) have a critical role in the progression
of several human cancers, including Squamous Non-Small-Cell Lung Cancer (SQCLC).
Both non-selective and selective reversible FGFR inhibitors are under clinical investigation
for the treatment of patients with tumors harboring FGFR alterations. Despite their
potential efficacy, the clinical development of these drugs has encountered several
challenges, including toxicity, and the appearance of drug resistance. Recent efforts
have been directed at development of irreversible FGFR inhibitors, which have
the potential to exert superior anti-proliferative activity in tumors carrying FGFR
alterations. With this in mind, we synthetized, and investigated a set of novel
inhibitors possessing a warhead potentially able to covalently bind a cysteine in
the P-loop of FGFR. Among them, the chloroacetamide UPR1376 resulted able to
irreversible inhibit FGFR1 phosphorylation in FGFR1 over-expressing cells generated
from SQCLC SKMES-1 cells. In addition, this compound inhibited cell proliferation
in FGFR1-amplified H1581 cells with a potency higher than the reversible inhibitor
BGJ398 (infigratinib), while sparing FGFR1 low-expressing cells. The anti-proliferative
effects of UPR1376 were demonstrated in both 2D and 3D systems and were
associated with the inhibition of MAPK and AKT/mTOR signaling pathways. UPR1376
inhibited cell proliferation also in two BGJ398-resistant cell clones generated from
H1581 by chronic exposure to BGJ398, although at concentrations higher than
those effective in the parental cells, likely due to the persistent activation of
the MAPK pathway associated to NRAS amplification. Combined blockade of
FGFR1 and MAPK signaling, by UPR1376 and trametinib respectively, significantly
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enhanced the efficacy of UPR1376, providing a means of circumventing resistance
to FGFR1 inhibition. Our findings suggest that the insertion of a chloroacetamide
warhead on a suitable scaffold, as exemplified by UPR1376, is a valuable strategy to
develop a novel generation of FGFR inhibitors for the treatment of SQCLC patients with
FGFR alterations.
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INTRODUCTION
The Fibroblast Growth Factor Receptor (FGFR) tyrosine kinase
(TK) family consists of four members (FGFR1-4), activated
through 22 different FGF ligands, which regulate multiple
biological processes, including cell proliferation, migration,
differentiation, apoptosis, metabolism, and angiogenesis (1).
Upon ligand binding, FGFRs dimerize and activate a complex
downstream signaling, including mitogen activated protein
kinase (MAPK), phosphoinositide-3-kinase (PI3K)/Akt, and
signal transducer and activator of transcription (STAT) pathways
(2). Deregulation of FGFR signaling, via gene amplification,
overexpression, point mutations or chromosomal translocations
has been implicated in several human cancers, such as lung,
breast, prostate, and endometrial cancers (3). In lung cancer,
FGFR1 amplification is observed in 9–20% of cases of the
Squamous Non-Small-Cell Lung Cancer (SQCLC) histotype (3–
5). SQCLC is a challenging disease characterized by a marked
mutational complexity that renders difficult the development of
effectivemolecular-targeted therapies. Although immunotherapy
has recently shown great promise (6–9), platinum-based
regimens are still the standard of care 1st-line therapy for the
majority of patients. Therefore, the potential of FGFR signaling
as a therapeutic target in SQCLC warrants continued exploration
to provide a valuable treatment option at least for the subset of
patients carrying FGFR alterations.
Since the identification of FGFR as a relevant target for cancer
therapy, a number of FGFR inhibitors have been developed and
some are currently under clinical evaluation in various FGFR-
related tumors (10). The most clinically advanced compounds
are non-selective FGFR TKIs, such as dovitinib and the Food
and Drug Administration (FDA)-approved ponatinib, which
target other related TKs, including Vascular Endothelial Growth
Factor Receptors (VEGFRs) and Platelet Derived Growth Factor
Receptors (PDGFRs). Despite their potential efficacy, the clinical
success of these drugs is limited by the increased adverse
side effects associated with their broad inhibitory activity (2).
More recently, potent and highly selective FGFR inhibitors,
such as BGJ398 (infigratinib, Figure 1) and others, i.e., AZD-
4547 (11) and JNJ-42756493 [erdafitinib (12)], have shown
promising pre-clinical anti-tumor activity, thereby entering into
clinical investigation. However, although these agents display
a more favorable safety profile as compared to FGFR non-
selective inhibitors (13, 14), their clinical efficacy has not
been unequivocally demonstrated, with the less encouraging
results obtained in patients with FGFR1 amplification (15,
16). Moreover, as seen with other RTK inhibitors, the clinical
FIGURE 1 | Chemical structures of relevant inhibitors of FGFR.
benefit of FGFR-targeted therapies is inevitably hampered
by the emergence of acquired resistance (17), arising from
activation of by-pass signaling mechanisms or selection of
gatekeeper mutations that abrogate the drug inhibitory activity
on the receptor.
Inhibitors able to engage FGFR with an irreversible
mechanism of action have the potential to overcome the
effect of genetic alterations emerging in FGFR inhibitor-treated
tumors (18). The clinical experience gained in the field of EGFR
and BTK kinases (19) have shown that compounds of this kind
are more therapeutically effective than their reversible analogs,
in light of the following properties: (i) irreversible inhibitors
do not readily dissociate from the engaged target thanks to the
formation of a covalent bond; (ii) they cannot be displaced by
ATP once the covalent bond with the target is formed; (iii)
they sustain prolonged inhibition of the signaling pathways also
after elimination from the cells, as the inhibitory process can
be reverted only through the de novo synthesis of the protein
(20, 21). Recent attempts to develop irreversible inhibitors
of FGFR have led to the identification of acrylamide-based
compounds such as FIIN-2/FIIN-3 (18) and PRN1371 (22)
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(Figure 1), which alkylate a non-catalytic cysteine present in the
P-loop of FGFR isoforms (Cys488 in FGFR1). These compounds
show excellent anti-proliferative activity in a variety of lung
cancer cell lines with a potency comparable or superior to that
of the clinical candidate BGJ398 (18, 22). These compounds also
inhibited the growth of SQCLC cell lines resistant to BGJ398,
emerging as potentially useful for treating FGFR-dependent
cancers, such as cholangiocarcinoma or metastatic urothelial
cancer, after progression (23). In the present work, we report
and characterize a focused set of FGFR inhibitors based on the
1-(4-aminobenzyl)-pyrimido[4,5-d]pyrimidin-2-one core of
FIIN-2, equipped with warheads different from acrylamide, with
the aim to expand the arsenal of available irreversible agents
targeting FGFR.
MATERIALS AND METHODS
Cell Culture
The human NSCLC cell lines SKMES-1 and H1581 were
purchased from the American Type Culture Collection (ATCC,
Manassas, VA); ATCC authenticates the phenotypes of these
cell lines on a regular basis. FGFR1-over-expressing LENTI-
4 cells were generated from FGFR1-low-expressing SKMES-1
cells using a lentiviral vector system, as previously described
(24). BGJ398-resistant cells were generated from H1581 cells by
continuous culturing with increasing concentrations of BGJ398
up to 1µM, and were routinely maintained in the presence of
1µMBGJ398. All the cells were cultured in RPMI 1640 medium,
supplemented with 2mM L-glutamine, 10% fetal calf serum
(FCS), and 1% penicillin/streptomycin solution, and maintained
at 37◦C in a humidified atmosphere of 5% CO2 and 95% air.
Compounds
BGJ398 was provided by Novartis International AG (Basel,
Switzerland). FIIN-2 was purchased from Selleck Chemicals
(Houston, TX). UPR1371-76 were prepared as described in the
Supplementary Material. All the drugs were dissolved in DMSO
(Sigma-Aldrich, Saint Louis, MO) and diluted in fresh medium
before use. The final concentration of DMSO in medium never
exceeded 0.1 % (v/v) and equal amounts of the solvent were
added to control cells.
Western Blotting Analysis
Procedures for protein extraction, solubilization, and protein
analysis by 1-D PAGE are described elsewhere (25). Antibodies
against p-FGFRTyr653/654, FGFR1, p-ERK1/2Thr202/Tyr204,
ERK1/2, p-mTORSer2448, mTOR, p-AKTser473, AKT, p-
P70S6KThr389, P70S6K were from Cell Signaling Technology
(Beverly, MA); the antibody against actin was from Sigma-
Aldrich. HRP-conjugated secondary antibodies were from Pierce
(Rockford, IL) and chemiluminescence system (ImmobilionTM
Western Chemiluminescent HRP Substrate) was from Millipore
(Temecula, CA). The chemiluminescent signal was acquired
by C-DiGit R© Blot Scanner (LI-COR Biotechnology, Lincoln,
NE). Where indicated, phosphorylation levels were quantified
by Image StudioTM Software (LI-COR Biotechnology), and
normalized to the corresponding protein levels.
Autophosphorylation and Washout Assay
The cells, serum-starved for 24 h, were pre-incubated for 1 h with
the compounds at 1µM concentration and then stimulated for
15min with 25 ng/ml FGF2 (Miltenyi Biotec, Bergisch Gladbach,
Germany). For the washout assay, the cells, pre-incubated with
the compounds for 1 h, were extensively washed with PBS,
and then maintained in drug-free medium for additional 8 h
before stimulation with FGF2 for 15min. The cells were lysed
and equal amounts of cell protein extracts were analyzed by
Western blotting using a phospho-FGFR antibody. Membranes
were stripped and reprobed with anti-FGFR1 antibody.
Determination of Intracellular
Concentrations of Selected Compounds
The cells were plated at 1 × 106 cells cells/dish (25 cm2)
density. After 24 h, BGJ398, FIIN-2 or UPR1376 were added
to the culture medium (titled concentration: 1µM with DMSO
0.1% v/v). At the end of incubation, the compounds were
removed from the extracellular medium by washing the cells
for three times with 1mL aliquot of fresh medium. The cells
were treated using absolute EtOH (1.1mL at 4◦C) to obtain
intracellular extracts. The final cell extracts were centrifuged
(4◦C, 10,000 g, 5min) and collected. A fixed volume of ethanolic
extract was evaporated to dryness, dissolved in LC eluent and
injected into the LC/MS system for quantitative measurement
(see Supplementary Material). Cell proteins were quantified
after solubilization in NaOH 0.5N (2 mL/25 cm2 dish) by the
Bradford method.
Analysis of Cell Proliferation
Cell proliferation was evaluated by tetrazolium dye [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
Sigma Aldrich] assay, as previously described (26). The
concentration that inhibits 50% of cell proliferation (IC50)
was extrapolated from the dose-response curves calculated
from experimental points using Graph-Pad Prism version 6.0
software (GraphPad Software, San Diego, CA). The nature of
the interaction between UPR1376 and trametinib was calculated
using the Bliss additivism model (27). A theoretical dose-
response curve was calculated for combined inhibition using the
equation of Bliss = EA + EB-EA∗EB, where EA and EB are the
percent of inhibition vs. control obtained by UPR1376 (A) and
trametinib (B) alone and the E Bliss is the percent of inhibition
that would be expected if the combination was exactly additive. If
the combination effect is higher than the expected Bliss equation
value, the interaction is synergistic, while if the effect is lower, the
interaction is antagonistic. Otherwise, the effect is additive and
there is no interaction between the drugs.
Spheroid Generation
Spheroids were generated using LIPIDURE R©-COAT PLATE A-
U96 (NOF Corporation, Tokyo, Japan) as previously described
(28). Briefly, 500 cells were seeded in RPMI 1,640 medium
and after 3 days (T0) the spheroids were treated with
BGJ398, FIIN-2 or UPR1376 for further 10 days. The effect
of the drugs was evaluated in term of volume changes using
the Nikon Eclipse E400 Microscope with digital Net camera.
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The volume of spheroids was measured [D=(Dmax+Dmin)/2;
V = 4/3pi(D/2)3] using SpheroidSizer, a MATLAB-based and
open-source software application (29).
Analysis for the Presence of FGFR1
p.V561M Mutation
Genomic DNA was extracted from the cells using the QIAamp
DNA Mini Kit (Qiagen Inc., Valencia, CA, USA), and stored at
−20◦C until use. Primers were designed in FGFR1 exon 13 with
Primer3 software.
FGFR1-exon13 Forward 5′ tgctcgggaattttctggac 3′
FGFR1-exon13 Reverse 5′ caacgccaccacaagatgat 3′
Exon 13 of FGFR1 gene (GeneBank accession number
NM_023110) was amplified for each sample by Polymerase
Chain Reaction (PCR) using AmpliTaq Gold DNA Polymerase
(Applied Biosystems) following manufacturer’s protocol. PCR
conditions were the following: 95◦C for 10min, 15 cycles with
touch down protocol with annealing temperature (TA) from 63
to 56◦C and 35 cycles with TA at 56◦C. A final step of 10min
at 72◦C was performed. Genomic DNA was sequenced using a
CEQ Dye-Terminator Cycle Sequencing kit (Beckman Coulter
Inc., Miami, FL, USA) according to the manufacturer’s protocol.
Sequence alignments were performedwith the DNAStar program
(DNAStar Inc., Madison, WI, USA). All the sequence reactions
were performed using a CEQ XL2000 DNA Analysis System
(Beckman Coulter).
NRAS Amplification
The analysis of NRAS amplification was performed by a digital
droplet PCR (ddPCR), using a Copy Number Assay (BioRad R©,
Hercules, CA) following the manufacturer’s instructions.
NRAS assay (dHsaCP1000493, BioRad) was labeled in FAM,
and reference assay AP3B1 (dHsaCP2500348), chosen among
recommended reference assays by BioRad, was labeled in VIC.
Statistical Analysis
Statistical analyses were carried out using Graph-Pad Prism
version 6.0 software. Statistical significance of differences among
data was estimated by Student’s t-test and p-values are indicated
where appropriate in the figures and in their legends p < 0.05
were considered significant.
RESULTS
Chemistry
Starting from the structure of FIIN-2 (Figure 2A), we synthesized
a small set of new potential FGFR inhibitors replacing the
terminal acrylamide installed on the aminobenzyl pendant
of this compound with other chemical groups. Our design
strategy was based on two distinct approaches. With the
first, we masked the acrylamide warhead by preparing the 3-
aminopropanamide (3-APA) derivative UPR1371. The 3-APA
group is not itself capable to covalently bind nucleophiles,
but it can undergo selective activation in the intracellular
environment of cancer cells (30), releasing the acrylamide
group (Figure 2B). With the second, the acrylamide was
replaced by activated acetamides, i.e., by electrophilic groups
potentially able to alkylate the P-loop cysteine of FGFR
isoforms by nucleophilic substitution (Figure 2C), differently
from acrylamides which still alkylates cysteine residues, but with
a different mechanism, namely a Michael addition. This is the
case of 2-((1H-imidazol-2-yl)thio)acetamide UPR1372, 2-((1H-
tetrazol-5-yl)thio)acetamide UPR1373 and 2-chloroacetamide
UPR1376. Acetamides of this kind have been recently used by
our group to obtain irreversible inhibitors of EGFR (31–33)
that also possesses a critical cysteine at the ATP binding site.
The procedures employed to synthesize the title compounds,
along with their chemical characterization, are reported in the
Supplementary Material.
UPR1376 Inhibits FGFR1
Auto-Phosphorylation Irreversibly in
FGFR1 Over-Expressing SQCLC Cells
The newly synthesized compounds were analyzed for their
ability to inhibit FGFR auto-phosphorylation in LENTI-4 cells,
a FGFR1-over-expressing cell model generated in our lab from
SQCLC FGFR1 low-expressing SKMES-1 cells. As indicated
in Figure 3, all the compounds down-regulated FGF2-induced
phosphorylation of FGFR1 after 1 h of treatment, with an efficacy
comparable to that shown by the reversible FGFR inhibitor
BGJ398 and the irreversible reference inhibitor FIIN-2. To
test the irreversible activity of UPR1371-UPR1376 compounds,
wash-out experiments were performed in which LENTI-4 cells
were exposed to the drugs for 1 h, extensively washed with
PBS, and then incubated in drug-free medium for further
8 h before stimulation with FGF2. While UPR1371, 1372, and
1373 failed to maintain FGFR1 inhibition, allowing an almost
complete recovery of auto-phosphorylation after 8 h, UPR1376
was even more effective than FIIN-2 in sustaining the inhibition
of FGFR1 auto-phosphorylation (Figure 3), suggesting its ability
to covalently interact with the receptor. As expected, FGFR1
auto-phosphorylation was reversibly inhibited by BGJ398 and
recovered 8 h after BGJ398 withdrawal, although the restoration
was not complete, presumably because of the efficient trapping of
the drug into the cells (34).
To further characterize the biological activity of the most
interesting compounds (BGJ398, FIIN-2, and UPR1376), we
measured their intracellular level in LENTI-4 cells immediately
after 1 h of exposure to each inhibitor (nominal concentration of
1µM) or 8 h after washing the inhibitor from the extracellular
medium by LC/MS (see Supplementary Material). Measured
concentrations are summarized in Table 1. At both time
points, the chloroacetamide derivative UPR1376 displayed an
intracellular concentration significantly lower than BGJ398 or
FIIN-2. This could be ascribed to its lower metabolic stability,
as indicated by the residual compound concentration measured
in the cellular medium after 8 h, i.e., 69.4 ± 2.5 % for UPR1376,
90.2 ± 9.0 for BGJ398, and 85.1 ± 2.8 % for FIIN-2. In spite
of a lower intracellular concentration, UPR1376 resulted able
to inhibit FGFR auto-phosphorylation as effectively as BGJ398
and FIIN-2 at 1 h and even more than these two reference
compounds 8 h after compound removal. This suggests that
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FIGURE 2 | (A) Chemical formulas of tested compounds. (B) Hypothesized conversion of 3-APA group of UPR1371 in acrylamide of FIIN-2. (C) Putative mechanism
of action for acetamide derivatives UPR1372, UPR1373 and UPR1376. The leaving group installed on the acetamide fragment is colored in red.
FIGURE 3 | Inhibitory effects of UPR1371-UPR1376 on FGFR1
auto-phosphorylation in LENTI-4 cells. LENTI-4 cells, serum-deprived for 24 h,
were pre-treated with 1µM BGJ398, FIIN-2 or the newly synthesized FGFR
inhibitors (UPR1371-UPR1376). After 1 h, the cells were stimulated with FGF2
for further 15min, or extensively washed with PBS and stimulated with FGF2
for 15min after 8 h of incubation in fresh drug-free medium. At the end of the
treatments, the cells were lysed and the protein extracts were analyzed by
Western blotting for FGFR1 auto-phosphorylation. Results are representative
of three independent experiments. The immunoreactive spots were quantified
by densitometric analysis, ratios of p-FGFR/total FGFR were calculated and
values, expressed as percent vs. control, are reported.
TABLE 1 | Intracellular levels of selected FGFR inhibitors measured in LENTI-4
cells by LC/MS.
Cpds Intracellular concentration (pmol/mg prot)
1 h 8h
BGJ398 1,843 52
FIIN-2 1,132 95
UPR1376 109 4
LENTI-4 cells were incubated with 1µM solution of titled compound for 1 h. Intracellular
content was measured immediately after incubation and 8 h after removal of the
compound from the medium by extensive washing by LC/MS. Concentrations are
expressed as pmol of compound per mg of protein, determined using Bradford assay.
Results are representative of two independent experiments.
UPR1376 is more potent than BGJ398 and FIIN-2 in the auto-
phosphorylation assay.
UPR1376 Down-Regulates FGFR1
Signaling and Inhibits Cell Proliferation in
FGFR1-Amplified H1581 Cells
The anti-tumor activity of UPR1371-UPR1376 was then
evaluated in the NSCLC large cell carcinoma H1581 cell
line, a cell model that harbors focal amplification of FGFR1
and is exquisitely sensitive to FGFR1 inhibition. All the
compounds significantly inhibited cell proliferation with IC50
values in the nM range (Figure 4A). However, UPR1371 was
the least effective, showing an IC50 value of ∼55 nM; UPR1376
again demonstrated high efficacy, inhibiting cell proliferation
with an IC50 value lower than that obtained with BGJ398
treatment. These growth-inhibitory effects were associated with
the inhibition of FGFR1 phosphorylation, with consequent
down-regulation of downstream signaling (Figure 4B). In
particular, all the compounds were as effective as BGJ398
and FIIN-2 in inhibiting the MAPK pathway, as indicated by
the complete dephosphorylation of ERK1/2 proteins, whereas
the AKT pathway, with its downstream components mTOR
and p70S6K, was more strongly down-regulated by UPR1376.
Since UPR1376 appeared more effective than BGJ398 in two
dimensional (2D) cultures, we evaluated its anti-proliferative
activity also in three dimensional (3D) systems. As shown in
Figure 4C, we demonstrated that not only BGJ398 and FIIN-
2, but also UPR1376 completely inhibited the growth of tumor
spheroids generated from H1581 cells, confirming its efficacy as
an inhibitor of FGFR1-dependent cell growth.
Generation and Characterization of
BGJ398-Resistant H1581-Derived
Cell Clones
The efficacy of the newly synthesized compounds was also
evaluated in BGJ398-resistant cell clones generated from H1581
cells. Continuous exposure of H1581 cells to 50 nM BGJ398
initially led to the inhibition of cell proliferation associated
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FIGURE 4 | Effects of BGJ398, FIIN-2, and UPR1371-UPR1376 on cell growth and FGFR1 signaling in H1581 cells. (A) H1581 cells were treated with increasing
concentrations of the FGFR inhibitors (0.001 nM-10µM) and after 72 h cell proliferation was assessed by MTT assay. The IC50 values shown are means ± SD of at
least three independent experiments. (B) H1581 cells were treated with the FGFR inhibitors at 1µM for 6 h, and then protein lysates were analyzed by Western
blotting for the indicated proteins. Results are representative of two independent experiments. (C) H1581 cells were grown as tumor spheroids in the absence or
presence of BGJ398, FIIN-2, or UPR1376 at 10 nM. Spheroid volumes were measured at 3 days after seeding (T0), and after 4, 7, or 10 days of culture. The data are
means ± SD of four independent determinations. **p < 0.01, *** p < 0.001, **** p < 0.0001 for BGJ398 vs. control; ### p < 0.001, #### p < 0.0001 for FIIN-2
vs. control; §§§ p < 0.001, §§§§ p < 0.0001 for UPR1376 vs. control. Representative images of tumor spheroids at 10 days are shown.
with cell death. During culture, the concentration of BGJ398
was gradually increased up to 1µM, and after 3 months
of continuous treatment the selective pressure finally led to
the emergence of cells no longer sensitive to the drug. Two
independent cell clones were selected (H1581R1 and H1581R2),
which, in contrast with the parental cell line, could grow in
the presence of 1µM BGJ398 and showed an IC50 value for
cell proliferation > 4µM (Figure 5A). As shown in Figure 5B,
resistance of these cell clones to BGJ398 was associated with
a persistent phosphorylation of FGFR1 despite the presence
of BGJ398, in contrast with the almost complete inhibition
induced by the drug in sensitive H1581 parental cells. We
therefore performed Sanger sequencing of PCR products from
H1581R cell clones to evaluate whether the resistance to FGFR1
inhibition was due to the presence of the V561M mutation
at the gatekeeper residue located in the ATP-binding pocket
of the receptor (35–37). However, neither of the two clones
harbored such mutation (not shown), although the presence
of other drug-resistant mutations at the level of the FGFR1
receptor cannot be ruled out. In addition, we excluded the
activation of efflux pumps as a mechanism of resistance leading
to a reduced accumulation of BGJ398 in H1581R clones;
indeed, no difference in the intracellular concentration of the
drug emerged between the resistant clones and the parental
cells (Figure 5C).
Interestingly, both the AKT and MAPK pathways remained
activated in H1581R clones in the presence of BGJ398 in contrast
with the parental cells (Figure 5D); in addition, we found that
NRAS was amplified in both clones, i.e., 61 copies for H1581R1
and 69 copies for H1581R2 cells vs. 4.2 copies for H1581 cells
(Figure 5E), likely contributing to the resistant phenotype.
UPR1376 Inhibits Cell Growth in H1581R
Cell Clones and this Effect Is Enhanced by
the Combination With the MEK1/2
Inhibitor Trametinib
H1581R1 and H1581R2 cell clones were then analyzed for their
sensitivity to UPR1371-UPR1376 in comparison with FIIN-2. As
shown in Figure 6A, the irreversible reference compound slightly
affected cell proliferation; among our compounds, only UPR1376
showed amarked anti-tumor activity, inhibiting cell proliferation
almost completely at 1 µM.
We therefore focused our attention on UPR1376. We treated
the resistant cell clones with increasing concentrations of
UPR1376 and demonstrated that this compound inhibited cell
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FIGURE 5 | Characterization of BGJ398-resistant cell clones generated from H1581 cells. (A) H1581, H1581R1, and H1581R2 cells were incubated with increasing
concentrations of BGJ398 (0.001 nM−10µM). After 72 h, cell proliferation was assessed by MTT assay. The data are expressed as percent inhibition of cell
proliferation vs. control. (B) H1581, H1581R1, and H1581R2 cells were incubated in the absence or presence of 1µM BGJ398, and after 6 h protein lysates were
analyzed by Western blotting for FGFR1 phosphorylation. (C) H1581, H1581R1, and H1581R2 cells were incubated with 1µM BGJ398. Intracellular compound
content was measured after 6 h by LC/MS. Concentrations are expressed as pmol of compound per mg of protein, determined using Bradford assay. (D) H1581 cells
and H1581R clones were treated as in B and protein lysates were analyzed by Western blotting for the indicated proteins. (E) Genomic DNA was extracted from
H1581 cells and H1581R clones and analyzed for the presence of NRAS amplification by ddPCR. Results in A and C are means ± SD of three independent
experiments. Results in B and D are representative of three independent experiments.
proliferation in a dose-dependent manner in both H1581R1
and H1581R2 cells, with IC50 values of 220 and 312 nM,
respectively (Figure 6B). In addition, we evaluated whether
UPR1376 was effective in inhibiting cell growth also in
3D systems. As shown in Figure 6C, H1581R1 cells were
capable of growing as tumor spheroids in the presence of
BGJ398. FIIN-2 had no growth-inhibitory effect; in contrast,
UPR1376 induced a complete block of cell growth, confirming
its ability to circumvent resistance to BGJ398 in H1581-
derived cells.
Then we evaluated the effects of UPR1376 on FGFR1
signaling in comparison with BGJ398 and FIIN-2 (Figure 7A).
As expected, BGJ398 did not inhibit FGFR1 nor affected
downstream pathways in resistant clones. FIIN-2 marginally
affected FGFR1 phosphorylation and the downstream signaling,
thus justifying its low inhibitory activity on cell proliferation
on H1581R clones. In contrast, UPR1376 significantly inhibited
FGFR1 phosphorylation/activation in both cell clones and, to
some extent, also affected downstream pathways. In particular,
UPR1376 down-regulated the AKT pathway, as indicated
by the significant reduction of both p-AKT and p-p70S6K
levels; however, no inhibition on ERK1/2 phosphorylation was
observed, suggesting that reactivation of the MAPK pathway
occurred independently of FGFR1, likely due the emergence of
NRAS amplification (38).
These findings suggest that H1581R1 and H1581R2 cell clones
still rely on FGFR1 and downstream AKT signaling for their
proliferation. However, it is worth noting that the resistant
clones were less sensitive to UPR1376 than the parental cells
(IC50 values of 220 nM for H1581R1 clone and 312 nM for
H1581R2 clone vs. 0.8 nM for inhibitor-sensitive H1581 cells),
suggesting that a contribution to cell growth in the resistant
cells may also derive from MAPK signaling through FGFR1-
independent mechanisms.
The persistent activation of the MAPK pathway in BGJ398-
resistant cell clones provided the rationale for combining
UPR1376 with trametinib, a highly specific inhibitor of MEK1/2
proteins, which are components of the MAPK signaling.
H1581R1 cells were exposed to increasing concentrations of
UPR1376 combined with a fixed concentration of trametinib,
chosen on the basis of a dose-response curve of proliferation
previously determined (not shown). According to the Bliss
experimental model, such combination produced synergistic
anti-proliferative effects (Figure 7B). The stronger efficacy
of the combination compared to the single treatments was
associated with the simultaneous down-regulation of the AKT
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FIGURE 6 | Effects of UPR1371-UPR1376 on cell growth in BGJ398-resistant H1581R1 and H1581R2 cell clones. (A) H1581R1 and H1581R2 cells were incubated
with FIIN-2 reference inhibitor or UPR1371-UPR1376 compounds at 1µM. After 72 h, cell proliferation was assessed by MTT assay. (B) H1581R1 and H1581R2 cells
were incubated with increasing concentrations of UPR1376 (1–1,000 nM). After 72 h, cell proliferation was assessed by MTT assay. (C) H1581R1 cells were grown as
tumor spheroids in the presence of 1µM BGJ398, FIIN-2 or UPR1376. Spheroid volumes were measured at 3 days after seeding (T0), and after 4, 7, or 10 days of
culture. **p < 0.01, ****p < 0.0001 vs. BGJ398-treated cells. Representative images of tumor spheroids at 10 days are shown. The data in A, and B are expressed as
percent inhibition of cell proliferation vs. control and are means ± SD of at least three independent experiments. The data in C are means ± SD of four
independent determinations.
FIGURE 7 | Effects of FGFR inhibitors on cell signaling and effects of UPR1376 combined with trametinib in BGJ398-resistant cell clones. (A) H1581R1 and H1581R2
cells were incubated in the absence or presence of 1µM BGJ398, FIIN-2 or UPR1376. After 6 h the cells were lysed and the protein extracts were analyzed by Western
blotting for the indicated proteins. (B)H1581R1 cells were incubated with increasing concentrations of UPR1376 (0.01–1,000 nM) in combination with 100 nM trametinib.
After 72 h cell proliferation was assessed by MTT assay. The effect of the drug combination was evaluated using the Bliss interaction model. **p < 0.01, ****p < 0.0001
vs. the corresponding points of the Bliss curve. (C) H1581R1 cells were incubated with 1µM UPR1376, 100 nM trametinib or a combination of both. After 6 h the
cells were lysed and the protein extracts were analyzed by Western blotting for the indicated proteins. Results are representative of three independent experiments.
pathway, mediated by UPR1376 through FGFR1 inhibition, and
the MAPK pathway, mediated by trametinib (Figure 7C). Of
note, trametinib increased AKT phosphorylation, which was
completely inhibited by UPR1376 treatment. Altogether these
results suggest that treatment with UPR1376 may be an effective
therapeutic approach to overcome resistance to BGJ398 and
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that its efficacy may be further improved by combination with
trametinib when the resistance is also associated with persistent
activation of the MAPK pathway.
DISCUSSION
Aberrant activation of FGFR signaling has been demonstrated
to play a key role in sustaining the growth of multiple
cancers, including SQCLC, thereby offering novel opportunities
for targeted therapeutic intervention. Both non-selective and
selective FGFR inhibitors have shown strong anti-tumor activity
in pre-clinical studies and are currently being evaluated in
clinical trials for the treatment of patients with tumors carrying
FGFR alterations. Although promising results are emerging from
these studies, several challenges are being faced, including the
selection of patients most likely to respond to FGFR inhibitors,
the management of toxicity profiles, and the appearance of drug
resistance (17, 22).
Recently, the development of irreversible FGFR inhibitors
has received growing attention due to their increased efficiency,
functional selectivity, and ability to circumvent acquired
resistance (39).
In this study, starting from 1-(4-aminobenzyl)-pyrimido[4,5-
d] pyrimidin-2-one core of FIIN-2, we synthesized a set of
four inhibitors of FGFR in which the acrylamide warhead
present in FIIN-2 was replaced by a 3-APA group (i.e.,
UPR1371), potentially able to generate an acrylamide in cancer
cells (30), or by activated acetamides (i.e., UPR1372, 1373,
and 1376), potentially able to alkylate the P-loop cysteine of
FGFR by nucleophilic substitution. In LENTI-4 cells, a FGFR1-
over-expressing SQCLC cell model generated in our lab, we
found that incubation with UPR1371 failed to give persistent
inhibition of FGFR1 suggesting that, in this SQCLC cell model,
the conversion of the 3-APA group in acrylamide did not
occur. Also the 2-(imidazol-2-ylthio)acetamide UPR1372 and
the 2-(tetrazol-5-ylthio)acetamide UPR1373 failed to irreversibly
inhibit FGFR1. In fact, 8 h after their removal from the treated
cells, the recovery of FGFR1 activity was nearly complete,
with phosphorylation levels approaching (UPR1372, UPR1373)
or overcoming (UPR1371) the 90% of the control. The
heteroarylthio acetamide group of UPR1372 and UPR1373 had
been devised as warheads with very low reactivity; the present
results show that higher reactivity is needed to get irreversible
inhibition of FGFR. On the other hand, the chloroacetamide
derivative UPR1376 was able to maintain FGFR1 significantly
inhibited after its removal from the cells. The comparison of the
auto-phosphorylation levels of FGFR at 8 h between UPR1376
(33% vs. control) and FIIN-2 (49% vs. control) indicated that
the former compound was more effective than the latter in
irreversibly inhibiting FGFR1. In light of these data, taking
into consideration the well-known reactivity of chloroacetamides
toward thiols in solution (40), and within the kinase active site
(41), we speculated that the higher activity of UPR1376 may
arise from a more efficient alkylation of the P-loop cysteine of
FGFR1 compared to the FIIN-2 compound. Although additional
experiments have to be performed to validate this hypothesis,
a covalent interaction between FGFR1 and UPR1376 appears
very likely. The good metabolic stability displayed by UPR1376
in cellular medium suggests that this compound might be able
to engage FGFR in the malignant tissue when administered
in vivo. On support of this, an EGFR inhibitor featured by a
similar chloroacetamide warhead has been successfully used in
the treatment of a mouse xenograft model of NSCLC (42).
In light of the prominent reactivity of chloroacetamide, we
preliminary evaluated the toxicity of UPR1376 by testing it on
SQCLC SKMES-1 cells expressing low levels of FGFR1. This
compound did not affect the proliferation of SKMES-1 cells
up to 1µM (Supplementary Figure 1), similarly to what had
been observed for BGJ398 and FIIN-2, indicating the selective
targeting of FGFR1 and its isoforms.
UPR1376 demonstrated a significant anti-proliferative activity
in H1581 NSCLC cells harboring FGFR1 amplification in both
2D and 3D systems. Most importantly, UPR1376 was shown
to restore sensitivity to FGFR1 inhibition in H1581-derived
cell clones generated through chronic exposure to BGJ398 and
become resistant to both BGJ398 and the irreversible reference
inhibitor FIIN-2.
To date, multiplemechanisms of resistance to FGFR inhibitors
have been described, mostly in pre-clinical studies, which can
be related to the activation of compensatory signaling or the
appearance of gatekeeper mutations in the FGFR receptors
themselves (14).
In H1581 cells sensitive to FGFR1 inhibition UPR1376, as
well as BGJ398 and FIIN-2, inhibited either the MAPK or the
AKT/mTOR pathways downstream of FGFR1. In H1581R cell
clones, resistance to BGJ398 was associated with the maintenance
of FGFR1 phosphorylation and with the persistent activation
of both signaling cascades. The inability of BGJ398 to suppress
FGFR1 activation was not due to the acquisition of the gatekeeper
V561Mmutation, previously shown to confer resistance to FGFR
inhibitors in different cancer models (35–37). However, we
cannot exclude the presence of other mutations at FGFR1 level.
Recently, the increased expression of the drug efflux transporter
ABCG2 has been identified as an additional mechanism of
resistance to the selective FGFR inhibitor AZD4547 (43).
However, it does not seem to be the case for H1581R cell clones,
since the intracellular accumulation of BGJ398 in these cells
is comparable to that observed in the parental cells. H1581R
cell clones acquired cross-resistance also to the irreversible
inhibitor FIIN-2. UPR1376, in contrast with BGJ398 and
FIIN-2, significantly inhibited the phosphorylation/activation
of FGFR1 and the downstream AKT/mTOR pathway, thus
impairing cell proliferation. A prominent role for AKT/mTOR
in FGFR signaling has been previously demonstrated in cancer
in a number of studies (24, 44–46). In addition, activation of
AKT in cancer cell lines carrying activating FGFR alterations
has been reported as a mechanism of acquired resistance to
BGJ398, which can be efficaciously reverted by treatment with
an AKT inhibitor (47). In H1581R clones, not AKT but MAPK
signaling was activated independently of FGFR1, being ERK1/2
phosphorylation maintained also in the presence of UPR1376-
mediated inhibition of FGFR1. Interestingly we found that such
up-regulation was associated with NRAS amplification.
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The persistent activation ofMAPK signaling likely contributes
to BGJ398 resistance in H1581R clones, also reducing to
some extent their sensitivity to UPR1376 in comparison
with the parental cells. Indeed, the anti-tumor efficacy of
UPR1376 was greatly improved by the combination with the
specific MEK1/2 inhibitor trametinib. Recently, reactivation of
MAPK pathway, mediated by NRAS amplification or MET
transcriptional regulation, has been linked to the emergence of
resistance to FGFR inhibitors in FGFR1-amplified lung cancer
cell models (38). In these cells, co-treatment with trametinib
or the MET inhibitor crizotinib restored the sensitivity to
BGJ398 by inhibiting the MAPK signaling in a direct or indirect
fashion, respectively.
It is worth noting that treatment with trametinib alone,
while inhibiting the MAPK signaling, increased AKT
phosphorylation/activation in H1581R cells, resulting in a
limited efficacy; UPR1376, blocking FGFR1 signaling, completely
reverted this effect leading to a synergistic impairment of cell
growth. Based on these findings, it is conceivable that the
simultaneous inhibition of FGFR/AKT and MAPK signaling
is required to achieve a significant anti-proliferative response,
overcoming the resistance to FGFR inhibitors.
Collectively our results suggest the concomitance of different
mechanisms of resistance in H1581R cell clones. This is in line
with the results from a recent study describing a SQCLC cell
model of acquired resistance to FGFR inhibitors, in which the
activation of the MET/MAPK axis co-exists with an independent
change of the AKT1 gene leading to the activation of AKT
signaling (48).
These observations support the notion that the emergence of
multiple genetic lesions within the same cells may represent a
common mechanism of resistance requiring a combined therapy
intervention to restore tumor cell responsiveness.
CONCLUSIONS
Because of the recognized role of FGFR signaling in cancer
progression, intensive efforts are being made to develop
effective FGFR-targeted therapies, which are especially urgent
for challenging-to-treat cancers, like SQCLC, that still have few
treatment options available. In this study, among the reported
compounds, chloroacetamide UPR1376 emerged as a promising
irreversible inhibitor of FGFR able to block proliferation of
FGFR1-amplified H1581 cells with a potency higher than
BGJ398, while sparing FGFR1 low-expressing cells. Interestingly,
in two distinct H1581-derived clones resistant to BGJ398,
UPR1376 inhibited proliferation at nanomolar concentration, an
effect that was strongly enhanced by trametinib. Collectively,
our results suggest that the insertion of a chloroacetamide
warhead on a suitable scaffold is a viable strategy to find a novel
generation of FGFR inhibitors, which may offer new therapeutic
opportunities for treating SQCLC patients with FGFR alterations
and overcoming acquired resistance.
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